Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J H Porter

Showing results (171-180 of 232) with videos related to

Pageof 24
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 9, 2014
Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategiesSifei Han, Tim Quach, Luojuan Hu, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 20, 2017
Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection siteGemma M Ryan, Victoria M McLeod, Dharmini Mehta, et al.
Molecular Pharmaceutics|February 13, 2016
Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological ActivityLinda J Chan, David B Ascher, Rajbharan Yadav, et al.
Biomaterials|April 23, 2018
Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistributionSophie C Larnaudie, Joaquin Sanchis, Tri-Hung Nguyen, et al.
Molecular Pharmaceutics|September 30, 2014
An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulationsMette U Anby, Tri-Hung Nguyen, Yan Yan Yeap, et al.
Molecular Pharmaceutics|January 12, 2012
Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor modelsLisa M Kaminskas, Victoria M McLeod, Brian D Kelly, et al.
Journal of Neurochemistry|November 7, 2017
Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid dietsYijun Pan, Kwok H C Choy, Philip J Marriott, et al.
Molecular Pharmaceutics|February 4, 2015
PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administrationLinda J Chan, Jürgen B Bulitta, David B Ascher, et al.
Pharmaceutical Research|March 13, 2009
Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolismNatalie L Trevaskis, David M Shackleford, William N Charman, et al.
ACS Chemical Biology|August 22, 2014
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding proteinRahul Patil, Aisha Laguerre, Jerome Wielens, et al.
Pageof 24

Showing results (171-180 of 232) with videos related to

Sort By:
Pageof 24
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 9, 2014
Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategiesSifei Han, Tim Quach, Luojuan Hu, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 20, 2017
Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection siteGemma M Ryan, Victoria M McLeod, Dharmini Mehta, et al.
Molecular Pharmaceutics|February 13, 2016
Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological ActivityLinda J Chan, David B Ascher, Rajbharan Yadav, et al.
Biomaterials|April 23, 2018
Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistributionSophie C Larnaudie, Joaquin Sanchis, Tri-Hung Nguyen, et al.
Molecular Pharmaceutics|September 30, 2014
An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulationsMette U Anby, Tri-Hung Nguyen, Yan Yan Yeap, et al.
Molecular Pharmaceutics|January 12, 2012
Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor modelsLisa M Kaminskas, Victoria M McLeod, Brian D Kelly, et al.
Journal of Neurochemistry|November 7, 2017
Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid dietsYijun Pan, Kwok H C Choy, Philip J Marriott, et al.
Molecular Pharmaceutics|February 4, 2015
PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administrationLinda J Chan, Jürgen B Bulitta, David B Ascher, et al.
Pharmaceutical Research|March 13, 2009
Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolismNatalie L Trevaskis, David M Shackleford, William N Charman, et al.
ACS Chemical Biology|August 22, 2014
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding proteinRahul Patil, Aisha Laguerre, Jerome Wielens, et al.
Pageof 24